Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Furuse

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Journal of Cancer Research and Clinical Oncology|February 18, 2017
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancerTakuji Okusaka, H Miyakawa, H Fujii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaB Sangro, S L Chan, R K Kelley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialC Morizane, T Okusaka, J Mizusawa, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Journal of Cancer Research and Clinical Oncology|February 18, 2017
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancerTakuji Okusaka, H Miyakawa, H Fujii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaB Sangro, S L Chan, R K Kelley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialC Morizane, T Okusaka, J Mizusawa, et al.
Pageof 6